Hot Flashes and Genetics: TACR3 Gene Linked to Menopause Symptoms

Hot flashes may feel like a hormonal lottery, but your genes have a measurable say. In a trans-ancestry study of nearly 150,000 postmenopausal women, researchers pinpointed the strongest genetic signal for hot flashes in TACR3, the gene encoding the neurokinin 3 receptor — the exact molecular target already blocked by a new class of non-hormonal hot flash drugs. The finding, published in Communications Medicine, confirms that neurokinin receptor antagonists hit the biological root of the problem rather than merely masking symptoms.

A 150,000-Person Genetic Sweep Lands on the Neurokinin 3 Receptor

The research team, led by Dr. Kerstin Werwath of Stanford University and Dr. Ryan Lawn of Harvard T.H. Chan School of Public Health, combined data across five cohorts of women aged 35–88. Four samples (42,489 women) used self-reported hot flashes; one large sample (107,071 women) used menopausal hormone therapy as a proxy — women often start hormone therapy specifically to treat hot flashes, making it a reasonable stand-in at scale.

Across ancestries, one signal towered above the rest: a locus on chromosome 4 within TACR3, the gene that codes for the neurokinin 3 receptor (NK3R). The p-value, 7.2×10⁻⁴¹, is far beyond the conventional genome-wide significance threshold of 5×10⁻⁸ — this is not a marginal association. A second chromosome 4 locus (rs13107507, p = 3.5×10⁻⁸) and genes including GRID1, NUDT4, and PHF21B also emerged. SNP-based heritability was estimated at 8% on the liability scale, meaning genetics accounts for a real but modest share of hot flash susceptibility.

Why Blocking Neurokinin 3 Receptors Cools Hot Flashes

The neurokinin story starts in the hypothalamus, the brain’s thermostat. Within a region called the KNDy (kisspeptin, neurokinin B, dynorphin) population of neurons, neurokinin B binds the NK3 receptor and widens the thermoneutral zone — the temperature band within which the body feels comfortable. When estrogen declines during perimenopause, KNDy neuron signaling is disrupted, the zone narrows dramatically, and small temperature changes trigger exaggerated heat-dumping responses: flushing, sweating, then chills.

Neurokinin 3 receptor antagonists restore that zone. Fezolinetant (Veozah) blocks NK3R specifically, while elinzanetant blocks NK1R and NK2R as well. Clinical trials of both drugs show meaningful reductions in hot flash frequency and severity, often within weeks. The new GWAS finding closes the loop: the very gene carrying the strongest hot flash signal encodes the receptor these drugs block. That convergence — independent basic science and population genetics pointing to the same target — is unusually strong evidence that NK3R signaling is a causal mechanism, not a bystander.

Notably, these drugs do not involve estrogen at all. For women with hormone-sensitive breast cancer, clotting risk, or a preference to avoid hormone therapy, a genetically validated non-hormonal option changes the conversation. Safety still warrants attention: a recent review raised questions about tumor risk signals with fezolinetant, and liver monitoring is part of its labeling.

Hot Flashes Share Genetic Ground With PTSD, Depression, and ADHD

One of the study’s most striking results is the psychiatric overlap. Using linkage disequilibrium score regression, the team found significant genetic correlations between hot flashes and PTSD (r_g = 0.25), depression (r_g = 0.21), ADHD (r_g = 0.22), and schizophrenia (r_g = 0.17).

These are correlations, not causal claims — shared genetics does not mean hot flashes cause depression. But the pattern fits known biology. Neurokinin signaling and the hypothalamic circuits involved in temperature regulation interact with stress-response systems, sleep, and mood regulation. It may help explain why women with trauma histories often report more severe menopausal symptoms, and why severe hot flashes are consistently linked with poor sleep and depressed mood. Clinically, it suggests women with hot flashes plus mood or trauma histories may need their symptoms treated as connected rather than separately.

What This Means in Practice for Women in Menopause

First, hot flashes are not “all in your head” — they have identifiable neurogenetic mechanisms. Second, the arsenal is growing: women can now weigh hormone therapy (where transdermal estrogen is increasingly the preferred route) against neurokinin antagonists, whose mechanism now carries genetic validation. Third, tell your clinician about hot flash severity honestly; untreated, severe vasomotor symptoms persist on average for years and erode sleep and quality of life. Lifestyle measures — weight management, exercise, and trigger tracking for caffeine and alcohol — remain useful adjuncts, but moderate-to-severe symptoms deserve evidence-based pharmacotherapy.

Frequently Asked Questions

What are neurokinin receptor antagonists and how do they treat hot flashes?

They are non-hormonal drugs (fezolinetant, elinzanetant) that block neurokinin receptors in the brain’s hypothalamus, widening the narrowed temperature-comfort zone caused by declining estrogen and reducing hot flash frequency and severity.

Did this study discover the drugs, or confirm them?

It confirmed them. The GWAS independently identified TACR3, the gene for the neurokinin 3 receptor, as the strongest genetic signal for hot flashes — the same receptor that existing NK3R-antagonist drugs were designed to block.

Are hot flashes genetic?

Partly. SNP heritability was estimated at about 8%, so genes contribute meaningfully, but menopause stage, estrogen decline, body weight, smoking, and environment drive most of the risk.

Can neurokinin antagonists be used by women who can’t take hormone therapy?

Yes — that is a key advantage. Because they don’t affect estrogen pathways, they offer an option for women with hormone-sensitive cancer histories or clotting concerns, though liver monitoring and a doctor’s review of risks remain necessary.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41495267/
https://pubmed.ncbi.nlm.nih.gov/41570166/
https://pubmed.ncbi.nlm.nih.gov/41418588/
https://pubmed.ncbi.nlm.nih.gov/41259888/
https://pubmed.ncbi.nlm.nih.gov/41222830/